

NO-CHARGE GENETIC TESTING FOR PEOPLE LIVING WITH ALS AND THEIR FAMILIES

SPONSORED BY BIOGEN AND OFFERED THROUGH INVITAE



Any patient with ALS—even those with seemingly sporadic disease—may have a genetic mutation¹



All patients with an ALS diagnosis are eligible for genetic testing, as are asymptomatic family members of individuals with ALS*

ALS IDENTIFIED PROGRAM FEATURES



ALS panel with more than 20 ALS-associated genes, with an optional add-on for additional, preliminary-evidence genetic mutations



Saliva, buccal swab, or blood sample collection kits arrive by mail with a prepaid return mailer



Portal provides easy access to order testing and view results



Turnaround time is 10 to 21 calendar days (14 days on average)



Results interpretation, background on genes and variants, and relevant literature can be obtained from Invitae

Visit ALSIdentified.com to learn more.

*Individuals 18 years of age or older in the US with a clinical diagnosis or family history of ALS are eligible. Includes Puerto Rico. Specimens for this program are accepted from the United States only. It is a requirement for a licensed, US HCP to submit the requisition form.

Third parties and commercial organizations including Biogen may receive de-identified patient data and genetic testing results from ALS Identified, but at no time will they receive identifiable patient information. Third parties and commercial organizations may receive contact information for healthcare professionals who refer patients to ALS Identified for genetic testing.

While third parties and commercial organizations may provide financial support for this program, tests and services are performed by Invitae. Healthcare professionals must confirm that patients meet certain criteria to use the program. Genetic testing is available in the US only. Healthcare professionals and patients who participate in this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any other products or services from Invitae or from third parties or commercial organizations.

Reference: 1. Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. *Genet Med.* 2017;19(3):267-274.